Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

ABSTRACT: Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

PROVIDER: PRJNA1076920 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27983341_1.fastq.gz	Fastqsanger.gz
	SRR27983341_2.fastq.gz	Fastqsanger.gz
	SRR27983342_1.fastq.gz	Fastqsanger.gz
	SRR27983342_2.fastq.gz	Fastqsanger.gz
	SRR27983343_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 264

Similar Datasets

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

Project description:Circulating Tumor Cells (CTCs) encompass multiple analytes, interrogated by sampling blood from patients with cancer. However, the clinical utility of tumor cell-based liquid biopsy has proven to be limited since CTCs are rare, and current technologies cannot process larger blood volumes required to isolate a sufficient number of tumor cells. We have described a high-throughput microfluidic prototype utilizing high-flow channels and amplification of cell sorting forces through magnetic lenses. Here, we apply this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volume of 5.83 liters from patients with metastatic cancer and achieving a median of 2,799 CTCs per patient. Isolation of many CTCs from individual patients enables characterization of their morphological and molecular heterogeneity, including cell and nuclear size and RNA expression. It also allows robust detection of gene copy number variation (CNV), a definitive cancer marker with potential diagnostic applications. High-volume microfluidic enrichment of CTCs constitutes a new dimension in liquid biopsies.

2024-08-27 | GSE255889 | GEO

Multi-parametric liquid biopsy approach

Project description:Multi-parametric liquid biopsy approach

| PRJEB39331 | ENA

Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Project description:Retinoblastoma Aqueous Humor Liquid Biopsy Repository

| PRJNA887892 | ENA

Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Project description:Retinoblastoma Aqueous Humor Liquid Biopsy Repository

| PRJNA887893 | ENA

Diagnostic accuracy of liquid biopsy in endometrial cancer

Project description:Diagnostic accuracy of liquid biopsy in endometrial cancer

| PRJNA767010 | ENA

Pre-analytical factors affecting the establishment of a single tube assay for multi-parameter liquid biopsy detection in melanoma patients

Project description:NGS liquid biopsy sequencing of miRNAs in total plasma and EV-associated miRNAs

2020-03-10 | GSE143231 | GEO

Early Detection of Colorectal Cancer Using Liquid Biopsy

Project description:Primary outcome(s): Diagnostic accuracy of colorectal cancer by liquid biopsy Study Design: Observational Study Model : Case-control, Time Perspective : Cross-sectional, Enrollment : 500, Biospecimen Retention : Collect & Archive- Sample with DNA, Biospecimen Description : Whole blood, colon tissue

| 2514159 | ecrin-mdr-crc

The Liquid Liver Biopsy: Detection of Circulating Epithelial Cells in Liver Disease

Project description:The Liquid Liver Biopsy: Detection of Circulating Epithelial Cells in Liver Disease

| PRJNA483004 | ENA

Characterizing DNA methylation signatures of retinoblastoma using the aqueous humor liquid biopsy

Project description:Characterizing DNA methylation signatures of retinoblastoma using the aqueous humor liquid biopsy

| PRJNA858063 | ENA

Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer

Project description:Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting in low compliance. Stool based tests have limited sensitivity for the detection of precancerous lesions. The CMx platform has been showed to be able to the detection of Circulating Tumor Cells (CTCs) in high sensitivity and specificity. In published studies, circulating Tumor Cells (CTCs) are captured and quantified in advanced-stages of colorectal cancer. In order to detect early and pre-cancer circulating tumor cells, we have developed an Automated Liquid Biopsy Platform that improves the detection of CTCs in early cancer stages. Therefore, this study goals are: 1) to establish a standard detection process utilizing the Automated Liquid Biopsy Platform. 2) Parallel comparison of laboratory manual operation and Automated Liquid Biopsy Platform. 3) Verify the feasibility of use of an Automated Liquid Biopsy Platform in the clinical setting.

| 2269165 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data